Novartis Snaps Up Corthera For $120M
Novartis AG revealed plans Tuesday to shell out $120 million for U.S. biopharmaceutical company Corthera Inc., a move that will give the Swiss drug giant exclusive worldwide rights to develop relaxin,...To view the full article, register now.
Already a subscriber? Click here to view full article